María D Arguisuelas1, Juan Francisco Lisón2, Daniel Sánchez-Zuriaga3, Isabel Martínez-Hurtado1, Julio Doménech-Fernández1,4. 1. Department of Physiotherapy, University CEU Cardenal Herrera, Valencia, Spain. 2. Department of Medicine, University CEU Cardenal Herrera, Valencia, Spain. 3. Department of Anatomy and Human Embryology, Universitat de València, Valencia, Spain. 4. Department of Orthopaedic Surgery, Hospital Arnau de Vilanova, Valencia, Spain.
Abstract
STUDY DESIGN: Double-blind, randomized parallel sham-controlled trial with concealed allocation and intention-to treat analysis. OBJECTIVE: To investigate the effects of an isolate myofascial release (MFR) protocol on pain, disability, and fear-avoidance beliefs in patients with chronic low back pain (CLBP). SUMMARY OF BACKGROUND DATA: MFR is a form of manual medicine widely used by physiotherapists in the management of different musculoskeletal pathologies. Up to this moment, no previous studies have reported the effects of an isolated MFR treatment in patients with CLBP. METHODS:Fifty-four participants, with nonspecific CLBP, were randomized to MFR group (n = 27) receiving four sessions of myofascial treatment, each lasting 40 minutes, and to control group (n = 27) receiving a sham MFR. Variables studied were pain measured by means Short Form McGill Pain Questionnaire (SF-MPQ) and visual analog scale (VAS), disability measured with Roland Morris Questionnaire, and fear-avoidance beliefs measured with Fear-Avoidance Beliefs Questionnaire. RESULTS: Subjects receiving MFR displayed significant improvements in pain (SF-MPQ) (mean difference -7.8; 95% confidence interval [CI]: -14.5 to -1.1, P = 0.023) and sensory SF-MPQ subscale (mean difference -6.1; 95% CI: -10.8 to -1.5, P = 0.011) compared to the sham group, but no differences were found in VAS between groups. Disability and the Fear-Avoidance Beliefs Questionnaire score also displayed a significant decrease in the MFR group (P < 0.05) as compared to sham MFR. CONCLUSION:MFR therapy produced a significant improvement in both pain and disability. Because the minimal clinically important differences in pain and disability are, however, included in the 95% CI, we cannot know whether this improvement is clinically relevant. LEVEL OF EVIDENCE: 2.
RCT Entities:
STUDY DESIGN: Double-blind, randomized parallel sham-controlled trial with concealed allocation and intention-to treat analysis. OBJECTIVE: To investigate the effects of an isolate myofascial release (MFR) protocol on pain, disability, and fear-avoidance beliefs in patients with chronic low back pain (CLBP). SUMMARY OF BACKGROUND DATA: MFR is a form of manual medicine widely used by physiotherapists in the management of different musculoskeletal pathologies. Up to this moment, no previous studies have reported the effects of an isolated MFR treatment in patients with CLBP. METHODS: Fifty-four participants, with nonspecific CLBP, were randomized to MFR group (n = 27) receiving four sessions of myofascial treatment, each lasting 40 minutes, and to control group (n = 27) receiving a sham MFR. Variables studied were pain measured by means Short Form McGill Pain Questionnaire (SF-MPQ) and visual analog scale (VAS), disability measured with Roland Morris Questionnaire, and fear-avoidance beliefs measured with Fear-Avoidance Beliefs Questionnaire. RESULTS: Subjects receiving MFR displayed significant improvements in pain (SF-MPQ) (mean difference -7.8; 95% confidence interval [CI]: -14.5 to -1.1, P = 0.023) and sensory SF-MPQ subscale (mean difference -6.1; 95% CI: -10.8 to -1.5, P = 0.011) compared to the sham group, but no differences were found in VAS between groups. Disability and the Fear-Avoidance Beliefs Questionnaire score also displayed a significant decrease in the MFR group (P < 0.05) as compared to sham MFR. CONCLUSION: MFR therapy produced a significant improvement in both pain and disability. Because the minimal clinically important differences in pain and disability are, however, included in the 95% CI, we cannot know whether this improvement is clinically relevant. LEVEL OF EVIDENCE: 2.
Authors: María Lourdes Peñalver-Barrios; Juan Francisco Lisón; Javier Ballester-Salvador; Julia Schmitt; Aida Ezzedinne-Angulo; María Dolores Arguisuelas; Julio Doménech Journal: PLoS One Date: 2021-05-13 Impact factor: 3.240
Authors: L Bellido-Fernández; J J Jiménez-Rejano; R Chillón-Martínez; M A Gómez-Benítez; M De-La-Casa-Almeida; M Rebollo-Salas Journal: Evid Based Complement Alternat Med Date: 2018-02-22 Impact factor: 2.629
Authors: I Martínez-Hurtado; M D Arguisuelas; P Almela-Notari; X Cortés; A Barrasa-Shaw; J C Campos-González; J F Lisón Journal: Sci Rep Date: 2019-05-13 Impact factor: 4.379